Key facts
- This page summarizes Wei-Wu He's Form 4 filing for CASI Pharmaceuticals, Inc..
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 17 Jun 2022, 16:14.
Wei-Wu He - 13 Jun 2022 Form 4 Insider Report for CASI Pharmaceuticals, Inc.
- Reporting relationship
- Chairman and CEO, Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 13 Jun 2022
- Net transaction value
- +$272,506
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2022, 16:14:02 UTC
- Prior SEC filing
- 19 Nov 2021
- Next SEC filing
- 18 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alexander Zukiwski, attorney-in-fact for Wei-Wu He
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Wei-Wu He filed Form 4 for CASI Pharmaceuticals, Inc. on 17 Jun 2022.
Change
- Previous filing in this sequence was filed on 19 Nov 2021.
- Current net transaction value: +$272,506.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CASI
transaction
Common Stock
Purchase
- Transaction value
- $107,092
- Shares
- +36,058
- Change %
- +6.5%
- Price
- $2.97*
- Shares after
- 592,457
- Date
- 13 Jun 2022
- Ownership
- Direct
- Footnotes
- F1, F2
CASI
transaction
Common Stock
Purchase
- Transaction value
- $6,414
- Shares
- +2,096
- Change %
- +0.35%
- Price
- $3.06*
- Shares after
- 594,553
- Date
- 14 Jun 2022
- Ownership
- Direct
- Footnotes
- F1, F2
CASI
transaction
Common Stock
Purchase
- Transaction value
- $159,000
- Shares
- +50,000
- Change %
- +8.4%
- Price
- $3.18*
- Shares after
- 644,553
- Date
- 15 Jun 2022
- Ownership
- Direct
- Footnotes
- F1, F2
CASI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 300,000
- Date
- 13 Jun 2022
- Ownership
- See Footnote
- Footnotes
- F2, F3
CASI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 753,234
- Date
- 13 Jun 2022
- Ownership
- See Footnote
- Footnotes
- F2, F4
CASI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 44,107
- Date
- 13 Jun 2022
- Ownership
- See Footnote
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The reported price is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.08 to $3.20 per share on June 15, 2022, $3.04 to $3.06 per share on June 14, 2022, and $2.87 to $3.00 per share on June 13, 2022. The Reporting Person undertakes to provide to the issuer, or any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F2
On June 1, 2022, the Issuer effected a 1-for-10 reverse stock split (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
Footnote F3
The shares are held indirectly in the name of ETP BioHealth III Fund, LP, a limited partnership of which the Reporting Person is the managing member of the general partner. The Reporting Person disclaims beneficial ownership over any shares held indirectly, except to the extent of his pecuniary interest therein and his filing is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or any other purposes.
Footnote F4
The shares are held indirectly in the name of ETP Global Fund LP, a limited partnership of which the Reporting Person is the managing member of the general partner. The Reporting Person disclaims beneficial ownership over any shares held indirectly, except to the extent of his pecuniary interest therein and his filing is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or any other purposes.
Footnote F5
The shares are held indirectly in the name of Emerging Technology Partners, LLC, an LLC entity of which the Reporting Person is the managing member. The Reporting Person disclaims beneficial ownership over any shares held indirectly, except to the extent of his pecuniary interest thein and his filing is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or any other purposes.
SEC remarks
Exhibit 24 - Power of Attorney